Sign In
Small logos Small logos
  • Home
  • Technology
    Artificial Intelligence
    Big Data
    Block Chain
    BYOD
    Cloud
    Cyber Security
    Data Center
    Digital Transformation
    Enterprise Mobility
    Enterprise Software
    IOT
    IT Services
  • Platforms
    The New Google Algorithm Update for 2021
    Google algorithm update for 2021
    Google

    Google is continuously making improvements to its algorithm and how websites are ranked on its organic search results page. This…

    5 Min Read
    Oracle Cloud Platform Now Validated for India Stack
    Service-Partner-Horizontal
    Oracle

    ORACLE OPENWORLD — Oracle today announced that the Oracle Cloud Platform has been validated to develop applications using India Stack…

    3 Min Read
    Oracle and AT&T Enter into Strategic Agreement
    Oracle

    Oracle today announced that AT&T signed an agreement to move thousands of its large scale internal databases to Oracle’s Cloud…

    3 Min Read
    IBM and Andrés Cepeda introduce First ‘Cognitive Music’ Project in Latin America
    IBM-Watson
    IBM

    IBM (NYSE: IBM) and Grammy-winning Colombian singer, songwriter and producer Andrés Cepeda will partner to collaboratively compose the artist’s next…

    3 Min Read
    Alpine Consulting Launches New eCommerce Website for Dana Rebecca
    IBM

    The new website will provide clients with the ability to more easily browse the latest innovations and designs in the…

    2 Min Read
    Check out more:
    • Google
    • HP
    • IBM
    • Oracle
  • Industry
    Banking & Insurance
    Biotech
    Construction
    Education
    Financial Services
    Healthcare
    Manufacturing
    Mining
    Public Sector
    Retail
    Telecom
    Utilities
  • Functions
    RISMA Systems: A Comprehensive Approach to Governance, Risk and Compliance
    Risma Systems
    ENTREPRENEUR VIEWSGDPR

    RISMA Systems was founded in 2014 by Lars Nybro Munksgaard, who initially developed a system that helped accountants and lawyers…

    9 Min Read
    Happiest Minds: A “Privacy by Design” approach is key to creating GDPR compliant businesses
    Happiest-Minds
    GDPR

    We are currently living in two different worlds – the digital world and the physical one. One day the twain…

    8 Min Read
    Gemserv: GDPR 2020 and Beyond
    Gemserv
    GDPR

    As a professional services business operating in a world driven by data and technology, Gemserv like many businesses,  finds itself…

    9 Min Read
    ECCENCA:GDPR IS STILL AN UNTAMED ANIMAL
    GDPR

    Enterprises often restrict their privacy management strategy to customer data only. Though it is the personal data of employees, spread…

    6 Min Read
    Boldon James: HOW ENTERPRISES CAN MITIGATE THE GROWING THREATS OF DATA
    GDPR

    As we fast approach the second anniversary of the implementation of GDPR, the impact it has had on businesses and…

    8 Min Read
    Check out more:
    • GDPR
  • Magazines
  • Entrepreneurs Views
  • Editor’s Bucket
  • Press Release
  • Micro Blog
Reading: Indian Biotech Company’s Nutraceutical Compound Shows Promising Use An Adjuvant To Treat COVID-19 In Randomized Clinical Trial.
Share
The CEO Views
Aa
  • Home
  • Magazines
  • Enterpreneurs Views
  • Editor’s Bucket
  • Press Release
  • Micro Blog
Search
  • Home
  • Technology
    • Artificial Intelligence
    • Big Data
    • Block Chain
    • BYOD
    • Cloud
    • Cyber Security
    • Data Center
    • Digital Transformation
    • Enterprise Mobility
    • Enterprise Software
    • IOT
    • IT Services
  • Platforms
    • Google
    • HP
    • IBM
    • Oracle
  • Industry
    • Banking & Insurance
    • Biotech
    • Construction
    • Education
    • Financial Services
    • Healthcare
    • Manufacturing
    • Mining
    • Public Sector
    • Retail
    • Telecom
    • Utilities
  • Functions
    • GDPR
  • Magazines
  • Entrepreneurs View
  • Editor’s Bucket
  • Press Release
  • Micro Blog
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
The CEO Views > Blog > Press Release > Indian Biotech Company’s Nutraceutical Compound Shows Promising Use An Adjuvant To Treat COVID-19 In Randomized Clinical Trial.
Press Release

Indian Biotech Company’s Nutraceutical Compound Shows Promising Use An Adjuvant To Treat COVID-19 In Randomized Clinical Trial.

CEO
Last updated: 2021/07/03 at 9:49 AM
CEO
Share
Nutraceutical Compound
SHARE

Vedicinals Pvt Ltd, a German-Indian biotech company based in Pune, India has recently announced the results of a WHO registered randomized clinical trial using its Indian regulatory authority approved nutraceutical compound called Vedicinals9.

https://www.vedicinals.com/wp-content/uploads/2021/06/FSSAI-central-license.pdf

https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ictrp-CTRI202010028364

The clinical trial which involved 124 patients with almost half using the nutraceutical product alongside standard approved COVID-19 treatment protocols showed better clinical outcomes including faster viral clearance, accelerated repair of lung damage, prevention of severe COVID-19 disease progression, improvements of various key biomarkers such as  IL-6 and CRP, faster resolution of clinical symptoms such as fever, cough, fatigue etc and also organ protection. https://www.vedicinals.com/human-clinical-trials/

Yogendra Kumar Choudhary, Chief Research Officer at Vedicinals Pvt Ltd  and CEO at Ethix Pharma Pvt Ltd commented, “The study demonstrated that 58% of patients in the Vedicinals-9 treatment group were discharged from hospital in the first 4 to 7 days of testing positive compared to the 37% standard care treatment group with improvement to 77.05% of normal X-ray findings in 12 days. Comparing the two treatments, a clear significant (p<0.05) difference was seen in the resolution of most symptoms, including fever, dry cough, fatigue, myalgia, sore throat, hypoxia, and dyspnea. The significant improvement (p<0.05) in the prognostic, inflammatory, and immunomodulatory biomarkers assessed as the change from baseline (CFB) to day 5, 12, and 45 in CRP, Total Antibody, IL-6 and change from baseline (CFB) to day 12 and 45 in Ferritin, D-dimer, CD4+ T cell, CD8+ T cell, CD19+ B cell, CD16+/CD56+ NK cell were reported in our randomized, open-label, multi centre, exploratory, Phase II b trial in mild to moderate COVID-19 patients. Overall, the early discharge, improved symptomatology and biomarkers indicate a possible positive effect for Vedicinals-9 as an add-on therapy for the management of COVID-19.”

https://www.vedicinals.com/lung-damage-in-covid-19-patients-lung/

A long-term evaluation of patients treated with Vedicinals9 showed that most had not developed long-term health complications typically associated with Long COVID.

Vedicinals9 consists of 9 bioactive molecules including Baicalin, Quercetin, Luteolin, Rutin, Hesperedin Curcumin, Epigallocatechin Gallate, Piperine, Glycyrrhizin. All these 9 bioactive molecules were selected based on silico studies, meta-analysis of past published studies, various studies on their drug target pathways and also their ability to be able to correct or stop various human host cellular pathways disruptions caused by the SARS-CoV-2 coronavirus. Details of these are found in the Vedicinals9 white paper. https://www.vedicinals.com/whitepaper/

These 9 bioactive molecules also have supporting published studies conducted by other research teams showing their individual efficacy against the SARS-CoV-2 coronavirus. https://www.vedicinals.com/bioactive-molecules-in-vedicinals-9/

Vedicinals9 has already gone thru extensive safety studies including toxicity and myocardial infarction studies involving Sprague Dawley Rats. The studies not only showed that Vedicinals9 was a safe product but there was actually data showing that VEDICINALS® 9 provided cardio protective benefits including significant protection of heart muscle tissues, blood vessels and the cardiovascular system.

https://www.vedicinals.com/safety-studies/

Vedicinals9 has already been used in a variety of hospital settings throughout India with positive results and is now available throughout the country at leading hospitals, clinics, pharmacies and also through Vedicinals own online shop.

The product is being sold at a net price of about US$135 for the Indian market for a set of 14 doses. This is a merely an introductory price for the next few months to help as many locals access the product at an affordable price. The product is priced much higher in overseas markets.

The product is currently undergoing observational clinical studies in Columbia, Brazil, Iran and Pakistan. A larger randomized human clinical trial is being planned for the United States in the state of Oregon and also in UK.

The product is also undergoing regulatory approval as a nutraceutical supplement in Japan, Thailand, Australia, Indonesia and Singapore.

A major deal is currently underway for one of the largest nutraceutical brands in the United States to develop the same product based on OEM and license of formulation agreement.

Prakash-Salunke

Prakash Salunke, Managing Director of Vedicinals Pvt Ltd said, “As of Today (21st June 2021) our product Vedicinals-9 is certified as a nutraceutical product in India by the FSSAI. Our FSSAI License no 10020028000199. As a result of the conclusion of our WHO registered randomized human clinical trial with results reported to both CTRI  India ((trial number CTRI – CTRI/2020/10/028364)  as will a WHO, we are in the midst of upgrading our certification to that as  Food For Specific Medical Purpose  (FSMP) which will soon be granted by the FSSAI. Our next obvious step is to continue further studies and trials in order to meet the requirements for compliance and certification of VEDICINALS-9 as a Phyto-pharmaceutical product. We are already receiving an overwhelming response for Vedicinals9 due to its efficacy and are now in the midst of making preparations to scale up production along with our partners.”

Joachim Gerlach

Joachim Gerlach, Chairman of Vedicinals Pvt Ltd added, “My main motivation to dedicate so much time and effort into the development of an adjuvant COVID THERAPEUTIC product is part of our corporate philosophy of long-lasting and genuine care for people’s wellbeing. Apart from vaccines, it is very important to also provide therapeutic solutions in order to fight this pandemic and the Long Covid conditions. I stand personally guarantee the honest and scientifically sound methods by which our company operates and the amount of scientific scrutinity we had gone through in the last 15 months to ensure that we have product that has efficacy against the COVID-19 disease and that is backed by scientific research and data. ”

Vedicinal9 as an adjuvant to treat COVID-19 will also put India back on the map again as a leading hub for pharmaceutical and nutraceutical development and production.

The product is also considered effective against emerging SARS-C0V-2 variants based on computation docking studies, studies of its individual constituents against the SARS-CoV-2 coronavirus new variants and also based on informal observation trials conducted.

From the clinical studies, it was also found that Vedicinals9 also protects from any harmful effects from the various drugs used in approved standard treatment protocols in India.

TAGGED: Covid-19, Nutraceutical Compound, Vedicinals Pvt Ltd
CEO July 3, 2021
Share this Article
Facebook Twitter LinkedIn Email Copy Link
Previous Article Blockchain How Can Blockchain Technology Help With Intellectual Property Protection?
Next Article How Consumerism and Customer Interaction Has Changed in the Last 20 Years How Consumerism and Customer Interaction Has Changed in the Last 20 Years
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Benefits of Artificial Intelligence for Cloud Security

Benefits of Artificial Intelligence for Cloud Security

Initiatives today need to be creative and use the latest…

June 27, 2022
Ligl
ENTREPRENEUR VIEWS
Ligl: Providing Seamless Automation for the End-to-End Hold and Discovery Workfiow Globally

Enterprise legal teams of every shape and size often struggle with the…

8 Min Read
Business Magazines
Micro Blog
A Definitive Guide to the Best Business Magazine

In today’s world, the more information you can get, the better it…

4 Min Read
TechVision21
ENTREPRENEUR VIEWS
TECHVISION21: Advancing Partner Innovations

In this era of rapid change and new challenges, companies need a…

7 Min Read
Sigmetrix
ENTREPRENEUR VIEWS
Sigmetrix

Mechanical variation exists due to the reality of small errors and imperfections…

8 Min Read

Skybridge Americas: Revolutionizing Customer Service With Talent and IT Innovation

Investing in customer experience has proven…

September 18, 2023

YELLOW BRICK ROAD: Unleashing Child’s Imagination With Unique Child Care Programs

Early childhood offers a critical window…

September 18, 2023

The ROI Of A Clean Workplace: Unseen Benefits Revealed

The ROI Of A Clean Workplace:…

September 18, 2023

PATRICK R. RICCARDS: Transforming The Teaching And Learning 0f American History

An exceptional visionary and dynamic leader,…

September 15, 2023

You Might Also Like

Press Release

Sekura.id announces partnership with BillBox

Mumbai, India. Sekura.id is thrilled to announce its partnership with BillBox, a trusted service provider in the digital payment industry…

4 Min Read
Press Release

The LGV Training Company Highlights Thriving HGV Industry Amidst Growth Opportunities

The HGV industry is currently experiencing a surge in growth and presents a multitude of opportunities for prospective drivers. Recent…

3 Min Read
Press Release

Telefónica Tech Identifies The Cybersecurity Landscape Shifts Amidst Rising Threats With The Help Of Recent Stats

The ever-changing Disaster Recovery landscape is witnessing a significant transformation in recent years. With businesses rapidly adopting cloud technologies and…

3 Min Read

Perle Systems Launches Native OCI Container Support in IRG Cellular Routers

PRINCETON, N.J. (July 18, 2023) Perle Systems, a global manufacturer of secure device networking hardware, is excited to announce the launch…

3 Min Read
Small logos Small logos

© 2023 All rights reserved. The CEO Views

  • About Us
  • Privacy Policy
  • Advertise with us
  • Reprints and Permissions
  • Business Magazines
  • Contact
Reading: Indian Biotech Company’s Nutraceutical Compound Shows Promising Use An Adjuvant To Treat COVID-19 In Randomized Clinical Trial.
Share

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?